Evidence map›Paper›PMID 40212678›Full record

ReviewFrontiers in oncology2025

The NIMA-related kinase family and cancer.

Haotian Li, Junhan Li, Yue Zhang, Ran Cao, Congcong Guo, Mingwen Jiao

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Mutational insights andFrontiers in bioinformatics · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Haotian LiDepartment of Endocrinology and Metabology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong First Medical University, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Institute of Nephrology, Jinan, China.
Junhan LiDepartment of Endocrinology and Metabology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong First Medical University, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Institute of Nephrology, Jinan, China.
Yue ZhangDepartment of Endocrinology and Metabology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong First Medical University, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Institute of Nephrology, Jinan, China.
Ran CaoSchool of Clinical Medicine, Shandong Second Medical University, Weifang, China.
Congcong GuoDepartment of Endocrinology and Metabology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong First Medical University, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Institute of Nephrology, Jinan, China.
Mingwen JiaoDepartment of General Surgery, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is a disease where cells begin to divide uncontrollably and spread to other parts of the body. Mitotic kinases play a crucial role in the initiation and progression of all human malignancies, making them common therapeutic targets. However, a significant portion of the human kinome has yet to be functionally studied in cancer systems. The NIMA-related kinase family (NEKs), consisting of 11 members distributed across different cellular regions, are important protein kinases that regulate mitotic processes. Emerging research suggests that NEK family members have potential key roles in various malignancies. This review systematically summarizes the expression and regulatory mechanisms of NEK family members in different cancer systems, highlighting that targeting NEKs holds promise as a new therapeutic approach for inhibiting cancer growth and metastasis.

Indexed as

cancermetastasismitosisNEK familyproliferationtherapeutic target

Identifiers

PMID40212678
PMCPMC11983647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.